Ipsen

IPN · Euronext Paris

Public Market Listing

IPNEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for Ipsen are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
3Approved
0Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
MET / VEGFR / AXL / RET (multi-kinase)Small molecule
Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular CarcinomaProstate Cancer
Clear Cell Renal Cell Carcinoma
Elafibranor(Iqirvo)
Approved
PPAR-alpha/PPAR-deltaSmall molecule
Cholestatic Liver Disease
Primary Biliary Cholangitis
Approved
Kinase InhibitorSmall molecule
Glioma

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Elafibranor · IqirvoPhase 3Primary Biliary Cholangitis
Est. primary completion 2026-12-17 · NCT06730061 · CT.gov ↗
What to watch
2027 (2)
May 2027 (1)
TovorafenibPhase 2Low-grade Glioma, Advanced Solid Tumor
Est. primary completion 2027-05-31 · NCT04775485 · CT.gov ↗
What to watch
June 2027 (1)
TovorafenibPhase 3Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Est. primary completion 2027-06 · NCT05566795 · CT.gov ↗
What to watch
2029 (1)
May 2029 (1)
Elafibranor · IqirvoPhase 3Primary Biliary Cholangitis (PBC)
Est. primary completion 2029-05-31 · NCT06016842 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
CabozantinibPhase 3Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET), Hepatocellular Carcinoma (HCC) …
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
2031 (2)
April 2031 (1)
Elafibranor · IqirvoPhase 3Primary Sclerosing Cholangitis
Est. primary completion 2031-04-30 · NCT07387549 · CT.gov ↗
What to watch
September 2031 (1)
Elafibranor · IqirvoPhase 2Primary Sclerosing Cholangitis
Est. primary completion 2031-09-23 · NCT05627362 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 July 2026Topline resultElafibranorELSPIRE phase IIIb topline
Ipsen · Source ↗

Financial reports

No financial reports recorded.